Suppr超能文献

晚期肾细胞癌的系统治疗。

Systemic therapy for advanced renal cell carcinoma.

机构信息

Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK.

出版信息

Ther Adv Med Oncol. 2009 Jul;1(1):15-27. doi: 10.1177/1758834009338430.

Abstract

Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers and is refractory to cytotoxic chemotherapy - immunotherapy has until recently been the standard of care for advanced disease. Randomised trials reported in the last 5 years have demonstrated that a number of agents including the monoclonal antibody, bevacizumab, and the kinase inhibitors - sorafenib sunitinib, temsirolimus and everolimus - are active in advanced RCC. Bevacizumab is directed against the vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, whilst sorafenib and sunitinib inhibit a number of targets including the VEGF and platelet-derived growth factor (PDGFR) receptor tyrosine kinases. Temsirolimus and everolimus inhibit the intracellular mammalian target of rapamycin (mTOR) kinase. Sunitinib and temsirolimus have demonstrated efficacy in comparison with immunotherapy in the first-line setting in patients with favourable and poor prognosis advanced disease respectively. In the second-line setting, everolimus has shown benefit over placebo in patients who progress following treatment with a VEGF receptor tyrosine kinase inhibitor and sorafenib has demonstrated efficacy in comparison with placebo in patients with immunotherapy-refractory disease. We review here recent clinical trial data and discuss future developments in the systemic treatment of RCC including combination and sequential therapy, adjuvant therapy, the role of biomarkers and the prospects for the development of rational mechanism-directed therapy in this disease.

摘要

肾细胞癌 (RCC) 约占所有癌症的 3%,对细胞毒性化疗具有抗性 - 免疫疗法直到最近一直是晚期疾病的标准治疗方法。过去 5 年报告的随机试验表明,包括单克隆抗体贝伐珠单抗和激酶抑制剂索拉非尼、舒尼替尼、替西罗莫司和依维莫司在内的多种药物在晚期 RCC 中具有活性。贝伐珠单抗针对血管内皮生长因子 (VEGF),这是血管生成的关键介质,而索拉非尼和舒尼替尼抑制包括 VEGF 和血小板衍生生长因子 (PDGFR) 受体酪氨酸激酶在内的多个靶点。替西罗莫司和依维莫司抑制细胞内哺乳动物雷帕霉素靶蛋白 (mTOR) 激酶。舒尼替尼和替西罗莫司在一线治疗中与免疫疗法相比,在预后良好和预后不良的晚期疾病患者中均显示出疗效。在二线治疗中,依维莫司在接受 VEGF 受体酪氨酸激酶抑制剂治疗后进展的患者中显示出优于安慰剂的益处,索拉非尼在免疫疗法难治性疾病患者中与安慰剂相比显示出疗效。我们在此回顾了最近的临床试验数据,并讨论了 RCC 系统治疗的未来发展,包括联合和序贯治疗、辅助治疗、生物标志物的作用以及在这种疾病中开发合理的机制导向治疗的前景。

相似文献

1
Systemic therapy for advanced renal cell carcinoma.
Ther Adv Med Oncol. 2009 Jul;1(1):15-27. doi: 10.1177/1758834009338430.
2
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27.
4
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Oncologist. 2011;16 Suppl 2(Suppl 2):32-44. doi: 10.1634/theoncologist.2011-S2-32.
6
Treatment options in renal cell carcinoma: past, present and future.
Ann Oncol. 2007 Sep;18 Suppl 10:x25-31. doi: 10.1093/annonc/mdm411.
8
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Cancer Treat Rev. 2016 Nov;50:109-117. doi: 10.1016/j.ctrv.2016.09.002. Epub 2016 Sep 10.
9
Inhibition of mTOR in kidney cancer.
Curr Oncol. 2009 May;16 Suppl 1(Suppl 1):S33-9. doi: 10.3747/co.v16i0.419.
10
Combination systemic therapy for advanced renal cell carcinoma.
Oncologist. 2009 Dec;14(12):1218-24. doi: 10.1634/theoncologist.2009-0105. Epub 2009 Nov 25.

引用本文的文献

3
Prognostic Benefit of Surgical Management of Renal Cell Carcinoma Invading the Inferior Vena Cava.
Indian J Surg Oncol. 2017 Mar;8(1):14-18. doi: 10.1007/s13193-016-0528-y. Epub 2016 May 4.
4
Formal synthesis of (-)-englerin A and cytotoxicity studies of truncated englerins.
Chem Asian J. 2012 May;7(5):1052-60. doi: 10.1002/asia.201101021. Epub 2012 Mar 13.
5
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Eur J Cancer. 2011 Dec;47(18):2706-14. doi: 10.1016/j.ejca.2011.09.002. Epub 2011 Nov 10.
6
Bayesian enrichment strategies for randomized discontinuation trials.
Biometrics. 2012 Mar;68(1):203-11. doi: 10.1111/j.1541-0420.2011.01623.x. Epub 2011 Jun 29.

本文引用的文献

2
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
J Urol. 2009 Feb;181(2):518-23; discussion 523. doi: 10.1016/j.juro.2008.10.001. Epub 2008 Dec 18.
3
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.
4
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Cancer. 2009 Jan 1;115(1):61-7. doi: 10.1002/cncr.24009.
7
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
8
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
9
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.
10
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.
Mol Cancer Ther. 2008 Jun;7(6):1347-54. doi: 10.1158/1535-7163.MCT-07-2408.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验